{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:04:14Z","timestamp":1793747054513,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14093-0","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:02:20Z","timestamp":1745316140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adeno-associated virus-clustered regularly interspaced short palindromic repeats\/cas9\u2011mediated ovarian cancer treatment targeting PD-L1"],"prefix":"10.1186","volume":"25","author":[{"given":"Tamaki","family":"Yahata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Toujima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Iwahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanizaki-Horiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyasu","family":"Kaisho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"14093_CR1","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10147-022-02163-3","volume":"27","author":"H Nakai","year":"2022","unstructured":"Nakai H, Matsumura N. Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. Int J Clin Oncol. 2022;27:1001\u201312. https:\/\/doi.org\/10.1007\/s10147-022-02163-3.","journal-title":"Int J Clin Oncol"},{"key":"14093_CR2","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s10147-022-02169-x","volume":"27","author":"H Nakai","year":"2022","unstructured":"Nakai H, Matsumura N. The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol. 2022;27:1120\u20136. https:\/\/doi.org\/10.1007\/s10147-022-02169-x.","journal-title":"Int J Clin Oncol"},{"key":"14093_CR3","unstructured":"American Cancer Society. Cancer Facts & Figures, P21-22. 2022;. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html (accessed on 18 July 2023)."},{"key":"14093_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7:306. https:\/\/doi.org\/10.1186\/s40425-019-0805-8.","journal-title":"J Immunother Cancer"},{"key":"14093_CR5","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1158\/1078-0432.CCR-20-0458","volume":"26","author":"A Osipov","year":"2020","unstructured":"Osipov A, Lim SJ, Popovic A, et al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: A meta-regression analysis. Clin Cancer Res. 2020;26:4842\u201351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0458.","journal-title":"Clin Cancer Res"},{"key":"14093_CR6","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.21873\/anticanres.12042","volume":"37","author":"A Gadducci","year":"2017","unstructured":"Gadducci A, Guerrieri ME. Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research. Anticancer Res. 2017;37:5955\u201365. https:\/\/doi.org\/10.21873\/anticanres.12042.","journal-title":"Anticancer Res"},{"key":"14093_CR7","doi-asserted-by":"crossref","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443\u20132454. https:\/\/doi.org\/0.1056\/NEJMoa1200690.","DOI":"10.1056\/NEJMoa1200690"},{"key":"14093_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365. https:\/\/doi.org\/10.1056\/NEJMoa1200694.","journal-title":"N Engl J Med"},{"key":"14093_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/cas.13958","volume":"110","author":"T Yahata","year":"2019","unstructured":"Yahata T, Mizoguchi M, Kimura A, et al. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats\/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Cancer Sci. 2019;110:1279\u201392. https:\/\/doi.org\/10.1111\/cas.13958.","journal-title":"Cancer Sci"},{"key":"14093_CR10","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","volume":"11","author":"M Behr","year":"2021","unstructured":"Behr M, Zhou J, Xu B, Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: progress and challenges. Acta Pharm Sin B. 2021;11:2150\u201371. https:\/\/doi.org\/10.1016\/j.apsb.2021.05.020.","journal-title":"Acta Pharm Sin B"},{"key":"14093_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-61779-370-7_6","volume":"807","author":"MS Sands","year":"2011","unstructured":"Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol. 2011;807:141\u201357. https:\/\/doi.org\/10.1007\/978-1-61779-370-7_6.","journal-title":"Methods Mol Biol"},{"key":"14093_CR12","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1038\/s41598-017-04625-5","volume":"7","author":"T Ohmori","year":"2017","unstructured":"Ohmori T, Nagao Y, Mizukami H, et al. CRISPR\/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep. 2017;7:4159. https:\/\/doi.org\/10.1038\/s41598-017-04625-5.","journal-title":"Sci Rep"},{"key":"14093_CR13","doi-asserted-by":"publisher","first-page":"198191","DOI":"10.1016\/j.virusres.2020.198191","volume":"290","author":"MEH Kayesh","year":"2020","unstructured":"Kayesh MEH, Amako Y, Hashem MA, et al. Development of an in vivo delivery system for CRISPR\/Cas9-mediated targeting of hepatitis B virus CccDNA. Virus Res. 2020;290:198191. https:\/\/doi.org\/10.1016\/j.virusres.2020.198191.","journal-title":"Virus Res"},{"key":"14093_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.braindev.2017.03.024","volume":"39","author":"JZ Wang","year":"2017","unstructured":"Wang JZ, Wu P, Shi ZM, Xu YL, Liu ZJ. The AAV-mediated and RNA-guided CRISPR\/Cas9 system for gene therapy of DMD and BMD. Brain Dev. 2017;39:547\u201356. https:\/\/doi.org\/10.1016\/j.braindev.2017.03.024.","journal-title":"Brain Dev"},{"key":"14093_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","volume":"25","author":"CE Nelson","year":"2019","unstructured":"Nelson CE, Wu Y, Gemberling MP, et al. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nat Med. 2019;25:427\u201332. https:\/\/doi.org\/10.1038\/s41591-019-0344-3.","journal-title":"Nat Med"},{"key":"14093_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","volume":"28","author":"CKW Lim","year":"2020","unstructured":"Lim CKW, Gapinske M, Brooks AK, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28:1177\u201389. https:\/\/doi.org\/10.1016\/j.ymthe.2020.01.005.","journal-title":"Mol Ther"},{"key":"14093_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","volume":"159","author":"RJ Platt","year":"2014","unstructured":"Platt RJ, Chen S, Zhou Y, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159:440\u201355. https:\/\/doi.org\/10.1016\/j.cell.2014.09.014.","journal-title":"Cell"},{"key":"14093_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3892\/ol.2018.9815","volume":"17","author":"T Yoshiba","year":"2019","unstructured":"Yoshiba T, Saga Y, Urabe M, et al. CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6. Oncol Lett. 2019;17:2197\u2013206. https:\/\/doi.org\/10.3892\/ol.2018.9815.","journal-title":"Oncol Lett"},{"key":"14093_CR19","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1038\/s41598-022-06025-w","volume":"12","author":"Z Noroozi","year":"2022","unstructured":"Noroozi Z, Shamsara M, Valipour E, et al. Antiproliferative effects of AAV-delivered CRISPR\/Cas9-based degradation of the HPV18-E6 gene in HeLa cells. Sci Rep. 2022;12:2224. https:\/\/doi.org\/10.1038\/s41598-022-06025-w.","journal-title":"Sci Rep"},{"key":"14093_CR20","doi-asserted-by":"publisher","first-page":"e0234147","DOI":"10.1371\/journal.pone.0234147","volume":"15","author":"M Tanaka","year":"2020","unstructured":"Tanaka M, Yamasaki T, Hasebe R, Suzuki A, Horiuchi M. Enhanced phosphorylation of PERK in primary cultured neurons as an autonomous neuronal response to prion infection. PLoS ONE. 2020;15:e0234147. https:\/\/doi.org\/10.1371\/journal.pone.0234147.","journal-title":"PLoS ONE"},{"key":"14093_CR21","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1093\/hmg\/ddz311","volume":"9","author":"H Li","year":"2020","unstructured":"Li H, Yuan S, Minegishi Y, et al. Novel mutations in malonyl-CoA-acyl carrier protein transacylase provoke autosomal recessive optic neuropathy. Hum Mol Genet. 2020;9:444\u201358. https:\/\/doi.org\/10.1093\/hmg\/ddz311.","journal-title":"Hum Mol Genet"},{"key":"14093_CR22","unstructured":"Fish R, Peggy J, Danneman M, Brown, Alicia Karas. Anesthesia and analgesia in laboratory animals, 2nd edition. American college of laboratory animal medicine. Academic Press, Cambridge, MA, USA, 2008; p86."},{"key":"14093_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.cgt.7700876","volume":"12","author":"C Li","year":"2005","unstructured":"Li C, Bowles DE, van Dyke T, Samulski RJ. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther. 2005;12:913\u201325. https:\/\/doi.org\/10.1038\/sj.cgt.7700876.","journal-title":"Cancer Gene Ther"},{"key":"14093_CR24","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","volume":"240","author":"JL Santiago-Ortiz","year":"2016","unstructured":"Santiago-Ortiz JL, Schaffer DV. Adeno-associated virus (AAV) vectors in cancer gene therapy. J Control Release. 2016;240:287\u2013301. https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.001.","journal-title":"J Control Release"},{"key":"14093_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3390\/genes9120575","volume":"9","author":"DJ Jiang","year":"2018","unstructured":"Jiang DJ, Xu CL, Tsang SH. Revolution in gene medicine therapy and genome surgery. Genes (Basel). 2018;9:575. https:\/\/doi.org\/10.3390\/genes9120575.","journal-title":"Genes (Basel)"},{"key":"14093_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","volume":"181","author":"D Wang","year":"2020","unstructured":"Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing. Strategies and in vivo delivery by AAV vectors. Cell. 2020;181:136\u201350. https:\/\/doi.org\/10.1016\/j.cell.2020.03.023.","journal-title":"Cell"},{"key":"14093_CR27","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.12688\/f1000research.11243.1","volume":"6","author":"CH Lau","year":"2017","unstructured":"Lau CH, Suh Y. In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. F1000Res. 2017;6:2153. https:\/\/doi.org\/10.12688\/f1000research.11243.1.","journal-title":"F1000Res"},{"key":"14093_CR28","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.3390\/v13081636","volume":"13","author":"AK Helfer-Hungerbuehler","year":"2021","unstructured":"Helfer-Hungerbuehler AK, Shah J, Meili T, Boenzli E, Li P, Hofmann-Lehmann R. Adeno-associated vector-delivered CRISPR\/SaCas9 system reduces feline leukemia virus production in vitro. Viruses. 2021;13:1636. https:\/\/doi.org\/10.3390\/v13081636.","journal-title":"Viruses"},{"key":"14093_CR29","doi-asserted-by":"publisher","unstructured":"Meumann N, Schmithals C, Elenschneider L et al. Hepatocellular carcinoma is a natural target for adeno-associated virus (aav) 2 vectors. Cancers (Basel). 2022; 14:427. https:\/\/doi.org\/10.3390\/cancers14020427","DOI":"10.3390\/cancers14020427"},{"key":"14093_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-024-02286-1","volume":"21","author":"M Hadi","year":"2024","unstructured":"Hadi M, Qutaiba B, Allela O, Jabari M, et al. Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma. Virol J. 2024;21:17. https:\/\/doi.org\/10.1186\/s12985-024-02286-1.","journal-title":"Virol J"},{"key":"14093_CR31","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/JVI.79.1.609-614.2005","volume":"79","author":"Y Kashiwakura","year":"2005","unstructured":"Kashiwakura Y, Tamayose K, Iwabuchi K, et al. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol. 2005;79:609\u201314. https:\/\/doi.org\/10.1128\/JVI.79.1.609-614.2005.","journal-title":"J Virol"},{"key":"14093_CR32","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1177\/1758834011422557","volume":"3","author":"JR Sierra","year":"2011","unstructured":"Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3:S21\u201335. https:\/\/doi.org\/10.1177\/1758834011422557.","journal-title":"Ther Adv Med Oncol"},{"key":"14093_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41388-023-02918-w","volume":"43","author":"CJ Wu","year":"2024","unstructured":"Wu CJ, Pan KF, Chen JQ, et al. Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment. Oncogene. 2024;43:511\u201323. https:\/\/doi.org\/10.1038\/s41388-023-02918-w.","journal-title":"Oncogene"},{"key":"14093_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ejso.2011.03.134","volume":"37","author":"PA Cascales Campos","year":"2011","unstructured":"Cascales Campos PA, Gil Mart\u00ednez J, Galindo Fern\u00e1ndez PJ, et al. Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer. Eur J Surg Oncol. 2011;37:543\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2011.03.134.","journal-title":"Eur J Surg Oncol"},{"key":"14093_CR35","doi-asserted-by":"publisher","first-page":"10078","DOI":"10.3390\/ijms231710078","volume":"23","author":"PQ Lim","year":"2022","unstructured":"Lim PQ, Han IH, Seow KM, Chen KH. Hyperthermic intraperitoneal chemotherapy (HIPEC): an overview of the molecular and cellular mechanisms of actions and effects on epithelial ovarian cancers. Int J Mol Sci. 2022;23:10078. https:\/\/doi.org\/10.3390\/ijms231710078.","journal-title":"Int J Mol Sci"},{"key":"14093_CR36","doi-asserted-by":"publisher","first-page":"e002051","DOI":"10.1136\/jitc-2020-002051","volume":"9","author":"RM Reyes","year":"2021","unstructured":"Reyes RM, Deng Y, Zhang D, et al. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from \u03b1PD-L1 and include tissue-selective \u0393\u03b4 T cell activation. J Immunother Cancer. 2021;9:e002051. https:\/\/doi.org\/10.1136\/jitc-2020-002051.","journal-title":"J Immunother Cancer"},{"key":"14093_CR37","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 Blockade. J Clin Invest. 2017;127:2930\u201340. https:\/\/doi.org\/10.1172\/JCI91190. Epub 2017 Jun 26.","journal-title":"J Clin Invest"},{"key":"14093_CR38","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359\u201370. https:\/\/doi.org\/10.1016\/j.molcel.2019.09.030.","journal-title":"Mol Cell"},{"key":"14093_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","volume":"24","author":"MN Theodoraki","year":"2018","unstructured":"Theodoraki MN, Yerneni SS, Hoffmann TK, Gooding WE, Whiteside TL. Clinical significance of PD-L1(+) exosomes in plasma of head and neck cancer patients. Clin Cancer Res. 2018;24:896\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2664.","journal-title":"Clin Cancer Res"},{"key":"14093_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2016.11.023","volume":"104","author":"Y Okuma","year":"2017","unstructured":"Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 2017;104:1\u20136. https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.023.","journal-title":"Lung Cancer"},{"key":"14093_CR41","unstructured":"Takara Bio Inc. AAVpro CRISPR\/Cas9 Helper Free System (AAV2). Available online: https:\/\/catalog.takara-bio.co.jp\/product\/basic_info.php?unitid=U100009139 (accessed on 18 July 2023)."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14093-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14093-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:02:26Z","timestamp":1745316146000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14093-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14093"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14093-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"29 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional Review Board Statement: All animal care and animal experimental procedures were performed in accordance with the Committee on Animal Care and Use of Wakayama Medical University (approval number 964) and all experiments with recombinant DNA technology were approved by the DNA Recombination Experiment Committee of Wakayama Medical University (approval numbers 29\u201334 and 2021-71).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"749"}}